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AbstrAct
The factors triggering pancreatic neuroendocrine tumor (PanNET) progression are 
largely unknown. Here we investigated the role and mechanisms of the sumoylation 
enhancing protein RSUME in PanNET tumorigenesis. Immunohistochemical studies 
showed that RSUME is strongly expressed in normal human pancreas, in particular 
in β-cells. RSUME expression is reduced in insulinomas and is nearly absent in other 
types of PanNETs suggesting a role in PanNET tumorigenesis. In human pancreatic 
neuroendocrine BON1 cells, RSUME stimulates hypoxia-inducible factor-1α (HIF-1α) 
and vascular endothelial growth factor-A (VEGF-A), which are key components of tumor 
neovascularisation. In contrast, RSUME suppresses nuclear factor-κB (NF-κB) and its 
target interleukin-8 (IL-8). Correspondingly, PanNET cells with RSUME knockdown 
showed decreased HIF-1α activity and increased NF-κB and IL-8 production leading 
to a moderate reduction of VEGF-A release as reduced HIF-1α/VEGF-A production is 
partly compensated by NF-κB/IL-8-induced VEGF-A. Notably, RSUME stabilizes the 
tumor suppressor PTEN, which is frequently lost in PanNETs and whose absence is 
associated with metastasis formation. In vivo orthotopic transplantation of PanNET 
cells with or without RSUME expression into nude mice showed that PanNETs without 
RSUME have reduced PTEN expression, grow faster and form multiple liver metastases. 
In sum, RSUME differentially regulates key components of PanNET formation suggesting 
that the observed loss of RSUME in advanced PanNETs is critically involved in PanNET 
tumorigenesis, particularly in metastasis formation.
INtrODUctION
Pancreatic neuroendocrine tumors (PanNETs) 
are rare and represent about 1 to 3% of all neoplasias 
of the pancreas [1, 2]. They derive from endocrine cells 
producing pancreatic hormones such as insulin, glucagon, 
gastrin, and others, and are correspondingly designated 
as insulinomas, glucagonomas, gastrinomas, etc. [1, 2]. 
About 50 to 60% of the tumors are functionally active 
and are diagnosed according to their symptoms caused 
by the hormonal hypersecretion [2, 3]. Functionally 
inactive PanNETs, if not accidentally detected, are mostly 
recognized in advanced stages when they have formed 
large invasive tumors and distant metastases [1, 2, 4]. 
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According to the WHO classification of 2010, all PanNETs 
are considered to be potentially malignant [1, 4]. Thus, the 
majority shows a malignant phenotype forming metastases 
in neighboring tissue or lymph nodes and almost 
40–50% have hepatic metastasis at diagnosis [1, 4]. As an 
exception, the majority of insulinomas appear as clinically 
benign and only approximately 10 % of all insulinomas 
are malignant [1, 2, 4]. The cumulative 5-year survival 
rate of patients with PanNETs has been reported to be 
83%, which drops to around 27% in advanced malignant 
stages with high Ki-67 index and the formation of distant 
metastases [1, 2, 4].
Complete resection of the primary tumors is the 
only curative therapeutic approach, however due to the 
formation of distant liver metastasis at diagnosis resection 
is only possible in a low percentage of patients [5, 6]. 
Palliative therapeutic options for inoperable pancreatic 
neuroendocrine tumors include treatment with somatostatin 
analogues, peptide receptor radionuclide therapy and 
chemotherapy using streptozocin- or temozolomide-based 
protocols [5, 6]. Due to the high degree of vascularization 
of PanNETs, the efficacy of anti-angiogenic acting drugs 
has also been approved [7]. Moreover, drugs targeting 
various receptor kinases or components of intracellular 
signaling pathways have been tested in recent clinical 
trials [7, 8]. However, the overall prognosis is still not 
satisfactory and better understanding of the molecular 
mechanisms of PanNETs development is urgent need in 
order to develop improved therapeutic approaches.
PanNETs are in some cases associated with 
hereditary genetic syndromes such as multiple 
endocrine neoplasia type I (MEN1), von Hippel-Lindau 
(VHL) syndrome, tuberous sclerosis syndrome or von 
Recklinghausen´s disease [1, 2, 9]. Inactivating somatic 
mutations of several genes have also been reported in 
PanNETs, in particular in the tumor suppressor MEN1, 
in the chromatin interaction proteins (death-domain 
associated protein) DAXX/ (alpha thalassemia/mental 
retardation syndrome X-linked) ATRX, and in negative 
regulators of the PI3K-Akt-mTOR signaling cascade, 
e.g. phosphatase and tensin homolog (PTEN) or tuberous 
sclerosis 2 (TSC2) [1, 2, 10–12]. Loss of function of 
the tumor suppressor gene PTEN is frequently found in 
PanNETs and is responsible for the over-activation of the 
PI3K-Akt-mTOR cascade [13, 14].
PanNETs are densely vascularized and express 
HIF-1α and VEGF-A [7, 15]. In contrast to many types 
of tumors, in which loss of differentiation goes along with 
an increase of microvessel density, less well-differentiated 
PanNETs are paradoxically less vascularized probably 
due to an impaired expression of the HIF-1/VEGF-A 
pathway [15]. VEGF-A is regulated by HIF-1, which plays 
a key role in tumor neovascularization and is composed 
of the constitutively expressed HIF-1β and the oxygen-
sensitive HIF-1α subunit [16]. The latter is continuously 
produced but subsequently degraded by ubiquitinylation 
under normoxic conditions. Under hypoxia, as it occurs in 
expanding tumors, this process is rapidly inhibited leading 
to the production of active an HIF-1 complex, which then 
induces the production of multiple angiogenic factors 
including VEGF-A [16].
We have previously shown that RSUME, the 
product of the RWDD3 gene, is a RWD containing 
protein that stabilizes and enhances HIF-1α [17–19]. 
RSUME also stabilizes I-κBα, the natural inhibitor of 
NF-κB, thereby inhibiting NF-κB [17, 19]. The latter 
is overexpressed in many types of tumors, including 
pancreatic adenocarcinomas, where it plays a key 
role in mediating inflammatory signals and triggering 
proliferation, angiogenesis and metastasis [20]. One of the 
NF-κB targets, interleukin-8 (IL-8), is strongly expressed 
in PanNETs, suggesting NF-κB over-activation [21]. 
Since pancreas strongly expresses RSUME [17], which 
is involved in the regulation of key molecules and 
processes influencing PanNETs, the aim of the study 
was to explore the expression and role of RSUME in 
PanNET tumorigenesis. We found that loss of RSUME is 
a characteristic of PanNETs and may contribute to tumor 
angiogenesis and metastasis.
rEsULts
rsUME is down-regulated in human pancreatic 
neuroendocrine tumors
Immunohistochemical studies showed strong 
RSUME expression in the insulin-positive cells of 
the Langerhans islets in the normal pancreas (n = 9) 
(Figure 1A, 1E), in which somatostatin-positive cells also 
expressed RSUME (Supplementary Figure 1). Moderate 
expression of RSUME was also found in exocrine 
acinar cells whereas RSUME was absent in ductal cells 
(Figure 1B–1E). Among 24 islet 1-positive PanNETs 
[22] investigated (11 G1 and 13 G2 tumors; Table 1, 
Supplementary Figure 2), scattered cytoplasmatic RSUME 
immunopositivity was observed in insulinomas (n = 7; 
Figure 1C, 1E) whereas RSUME was absent in the vast 
majority of the other PanNETs including 4 somatostatin 
expressing tumors (Figure 1B, 1D, 1E; Supplementary 
Figure 1). Thus, in comparison to the normal pancreas, 
RSUME expression is decreased in PanNETs (Figure 1F).
rsUME regulates angiogenesis through the 
HIF-1α/VEGF pathway
In neuroendocrine pancreatic BON1 cells, RSUME 
mRNA and protein was enhanced by hypoxia (1% O2; 
Figure 2A) or hypoxia mimicking conditions (CoCl2 
treatment, Supplementary Figure 3) through RSUME/ 
HIF-1 interaction (Supplementary Figure 4) as already 
shown in other cell types [17, 23]. Knocking down 
RSUME (BON1RSUME-KD) decreased basal and hypoxia-
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induced RSUME and HIF-1α mRNA and protein levels 
(Figure 2B, 2C), confirming the importance of RSUME in 
HIF-1α regulation. In comparison to the strong suppression 
of moderately inhibited basal and hypoxia-induced mRNA 
levels and secretion of VEGF-A (Figure 2D) suggesting 
the induction of a compensatory mechanism to preserve 
VEGF-A production. In neuroendocrine pancreatic QGP1 
cells, RSUME overexpression induced HIF-1a expression 
during hypoxia confirming the impact of RSUME on 
HIF-1α regulation (Supplementary Figure 5).
In HIF-1α deficient colon cancer cells, VEGF-A 
production is preserved by the pro-angiogenic cytokine 
IL-8 [24]. We found expression of IL-8 and its receptor 
CXCR2 in BON1 cells and in the human neuroendocrine 
carcinoma QGP1 cell line (Supplementary Figure 6). The 
CXCR2 inhibitor SB225002 significantly reduced basal 
Figure 1: rsUME expression is decreased in human pancreatic neuroendocrine tumors. Immunohistochemistry staining 
of RSUME in resected normal pancreas (A), PanNETs (b, Grade 2), insulinoma (c) and PanNET with a non-malignant normal region 
(D, Grade 1). (E) Co-staining of Insulin (green) and RSUME (red) in normal pancreas, insulinoma, and other types of PanNETs. Images 
are representative of three experiments with similar results. Scale bar 50 µm. (F) Summary of RSUME expression in normal pancreas, 
insulinoma and other types of PanNETs. The intensity of the staining was classified as negative (0), weakly (1+), medium (2+) and strongly 
positive (3+). All samples from this study were assessed by two different raters who were blinded to each other. See Table 1 for detailed 
patient information.
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and hypoxia-induced VEGF-A secretion (Supplementary 
Figure 7). RSUME knockdown increased IL-8 
transcription and secretion, which was further induced 
by hypoxia (Figure 2E). Increased levels of IL-8 can 
stimulate VEGF-A, which may explain that the loss of 
RSUME in PanNET cells has limited inhibitory effects on 
VEGF-A secretion despite strongly decreased HIF-1α.
RSUME negatively regulates NF-κB activity by 
enhancing IκBα sumoylation in PanNETs
IL-8 expression is stimulated by NF-κB [25]. 
RSUME overexpression inhibited TNFa-induced IL-8 
promoter activity and co-transfection with the I-κBα 
super repressor (I-κBα-SR) significantly attenuated this 
effect (Figure 3A, left). All these effects were completely 
abolished when the NF-κB binding site of the IL-8 
promoter was mutated, which further demonstrates 
that RSUME inhibits IL-8 activity through NF-κB in 
BON1 cells (Figure 3A, right). RSUME overexpression 
increased I-κBα sumoylation, an effect which was 
comparable to that of SUMO1 (Figure 3B, left, upper 
band, lanes 2 and 4). This effect was abolished when 
I-κBα was mutated at the SUMO1 conjunction target sites 
lysines 21 and 22 (Figure 3B, right, lane 1 and 2) [26] 
or overexpression of the RSUME-Mut (Y61A, P62A) 
Table 1: Clinicopathological features of PanNET patients
Diagnosis Grading Proliferation index
Hormone 
Expression
rsUME 
expression
PTEN 
level
PTEN 
subloc.
Islet1
1 PanNET G1 3% Not tested − − +++
2 PanNET G1 < 1% Not tested − ++ N + C +++
3
PanNET,
lymphnode 
metastasis
G2 15% No expression − ++ C +++
4 Insulinoma G1 3% Insulin+ ++ ++ C +++
5 PanNET G2 NA Not tested − +++
6 PanNET G2 NA Insulin neg. ++ + C +++
7 PanNET G1 1% Not tested − − +++
8 PanNET G2 4% Not tested − − +++
9 PanNET G2 NA
Serotonin+, 
Somatostatin+
Gastrin+
− + C +++
10 PanNET G2 3% Not tested − +++ C +
11 PanNET G2 10% Somatostatin+ − − +
12 PanNET G2 7% Insulin neg. + − ++
13 PanNET G1 < 2% Insulin neg. − ++ C ++
14 PanNET G2 15% No expression − − +++
15 PanNET G2 3% Somatostatin+ − − +++
16
PanNET,
lymphnode 
metastasis
G1 1% Glucagon+ − ++ C ++
17
PanNET,
lymphnode 
metastasis
G1 < 1% Somatostatin+ VIP − + N + C +++
18 PanNET G2 4% Serotonin+, Insulin neg. ++ − +++
19 Insulinoma G2 NA Insulin+ + − +++
20 Insulinoma G1 NA Insulin+ +++ + C −
21
Insulinoma, 
liver 
metastasis
G2 5% Insulin+ + − +++
22 Insulinoma G1 < 2% Insulin+ +++ − +++
23 Insulinoma G2 3% Insulin+ + ++ C +++
24 Insulinoma G1 NA Insulin+ +++ ++ C +++
PanNET: pancreatic neuroendocrine tumor; NA: not available; N: Nuclear staining; C: cytoplasm staining; subloc: 
sublocalization.
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where the highly conserved YPXXXP motif in the RWD 
domain of RSUME was mutated (Figure 3B, right, lane 3 
and 4) [17, 22]. Co-transfection with the SUMO1/sentrin 
specific peptidase 1 (SENP1), attenuated sumoylated 
I-κBα (Figure 3B, left, lanes 3, 5, 6) demonstrating 
that RSUME specifically affects I-κBα sumoylation. 
RSUME suppressed basal and TNFa-induced NF-κB 
transcriptional activity similar to SUMO1, and this effect 
was abolished by the I-κBα super-repressor (Figure 3C). 
In contrast, RSUME knockdown increased both basal 
and TNFa-induced NF-κB transcriptional activity 
(Figure 3D), further demonstrating the repressive role of 
RSUME on NF-κB activity in BON1 cells.
Western blot experiments were performed with 
cell extracts using antibodies against key components of 
the NF-κB pathway, including total and phosphorylated 
p65/RelA and I-κBα. RSUME knockdown increased 
phosphorylated I-κBα (Ser32/36) and p65/RelA (Ser536) 
levels (Figure 3E), indicating NF-κB activation. 
Furthermore, loss of RSUME is accompanied by increased 
p65/RelA (Ser536) nuclear translocation (Figure 3F), 
which is indicative of activated NF-κB.
RSUME enhances SUMO-directed PTEN 
sumoylation
NF-κB was previously shown to suppress PTEN 
[27], which is reduced in 16 of 24 of the PanNETs 
studied (Table 1). Since RSUME negatively regulates 
NF-κB activity, we investigated its role on PTEN 
transcription. RSUME overexpression in BON1 cells 
increased PTEN mRNA and protein levels and the 
Figure 2: Influence of RSUME on HIF-1α, VEGF-A and IL-8 production. RSUME mRNA and protein level (A) were 
stimulated during hypoxia (1% O2) for the indicated time points in BON1 cells. As expected RSUME mRNA and protein was down-
regulated and less sensitive to hypoxia in BON1 cells with RSUME knock-down (BON1RSUME-KD) compared to scramble siRNA trasfected 
cells (BON1Scramble) (b). HIF-1a mRNA and in particular hypoxia-induced HIF-1a protein production was strongly impaired in BON1RSUME-KD 
cells (c). Normoxic and hypoxic mRNA synthesis and secretion of VEGF-A was suppressed in BON1RSUME-KD cells (D) whereas IL-8 
mRNA and protein production was enhanced. (E). All experiments were performed three times and in B to E treatment time was 3 h for 
mRNA expression and 12 h for protein production studies, respectively. Results are expressed as mean ± SEM of triplicates for mRNA and 
quadruplicate for ELISA. *P < 0.05, **P < 0.01.
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Figure 3: RSUME negatively regulates NF-κB activity by enhancing sumoylation of IκBα. BON1 cells were transfected 
with IL-8-LUC (A, left) or IL-8 (NF-κB-mut)-LUC (A, right) reporter vector, RSUME or IκBα super repressor (I-κBα-SR) and β-gal 
plasmid. After 24 h, cells were stimulated with 10 ng/ml TNF-α for 6 h, and LUC activity was measured in the cell extracts. (b) BON1 
cells were co-transfected with I-κBα, I-κBα mutated at the SUMO1 conjunction target sites lysine 21 and 22 (K21, 22R), and the indicated 
expression vectors (including the SUMO1/sentrin specific peptidase 1 -SENP1), to analyze I-κBα sumoylation status in BON1 cells. After 
24 h, cell extracts were subjected to WB with anti-I-κBα antibody. β-actin was used as the loading control. (c) BON1 cells were transfected 
with NF-κB-LUC reporter vector, RSUME, HA-SUMO1 or I-κBα expression vectors. After 24 h, cells were stimulated with 10 ng/ml 
TNF-α for 6 h, and LUC activity was measured. (D) NF-κB-Luc activity in BON1RSUME-KD and BON1Scramble cells was measured with or 
without TNF-α (10 ng/ml, 6 h). All values were normalized to β-gal activity (mean ± SEM of 3 different experiments, t test). *P < 0.05, 
**P < 0.01 (E) Western blot experiments were performed with cell extracts were RSUME was knockdown and with Immunoblotting for 
NF-κB subunits (p65, p-p65(Ser536), I-κBα and pI-κBα (Ser32/36) in BON wild type, BON1RSUME-KD and BON1Scramble cells lysates. β-actin 
was used as the loading control. (F) Immunofluorescence for total and phosphor-p65 (Ser536) in BON1RSUME-KD and BON1Scramble cells. 
Antibodies used were indicated above each image with corresponding colors. DAPI staining was used to visualize the nucleus. Scale bars 
are equal to 10 μm. Each image is representative of three independent experiments with similar results.
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opposite was observed after RSUME knockdown 
(Figure 4A). In QGP1 cells RSUME overexpression also 
enhanced PTEN expression (Supplementary Figure 5). 
The functional significance of RSUME´s effect on PTEN 
is evidenced by the increased Akt phosphorylation in 
RSUME knockdown cells (Supplementary Figure 8). In 
addition, we observed a high migration band (~75 kDa, 
H-PTEN), which is regulated by RSUME, indicating 
posttranslational modification (Supplementary Figure 8). 
RSUME knockdown decreased total and 75kDa 
H-PTEN: total PTEN ratio (13.13 ± 4.77% vs. 5.97 ± 
1.95%, Supplementary Figure 8). We confirmed that 
the higher migration band at ~75 kDa is SUMO-PTEN 
by co-immunoprecipitation with SUMO2 (Figure 4B). 
An in vitro sumoylation assay revealed that the band 
detected between 75 and 100 kDa (~26 kDa for GST-tag) 
was SUMO2-modified PTEN, and this signal was 
further enhanced by RSUME (Figure 4C). A SUMO 
conjugation assay confirmed the increase in 75 kDa 
sumoylated PTEN levels in RSUME overexpressing 
cells (Figure 4D, lane 3). RSUME also enhanced 
SUMO1-mediated PTEN sumoylation, but to a lesser 
extent (Supplementary Figure 9). To further clarify the 
mechanisms through which RSUME regulates PTEN we 
used COS7 cells as we assume that the effects of RSUME 
on PTEN may be similar in each RSUME expressing cell 
type. RSUME-Mut (Y61A, P62A) failed to stimulate 
PTEN modification by SUMO2 (Figure 4D, lane 4). 
In silico prediction (SUMOplot™ Analysis Program) and 
previous reports [28, 29] revealed two major sumoylation 
conjugation sites (lysine 254 and lysine 266) in PTEN. 
Sumoylation deficient PTEN mutants (K254R, K266R, 
K254/266R) displayed variable sumoylation (Figure 4E, 
lanes 2–4). The expected ~75 kDa was observed in Ni-
NTA purified proteins when cells were co-transfected 
with wild type PTEN (WT-PTEN) and His-SUMO2. 
The single K254R mutant showed reduced sumoylation 
(Figure 4E, lane 2 vs. lane 1), which was further reduced 
in the double K254/266R mutant (lane 4). In contrast, 
the single K266R mutant (lane 3) had a minor effect on 
sumoylation, but exerts a synergistic effect with the K254 
site. RSUME overexpression strongly enhanced SUMO2-
induced sumoylation in the WT-PTEN construct (lane 5), 
but not in the double K254/266R mutant (lane 8). Co-
immunoprecipitation revealed a physical association 
between RSUME and PTEN in cells (Figure 4F).
RSUME increases PTEN stability by reducing its 
ubiquitination
We next investigated if the RSUME-induced PTEN 
sumoylation modulates PTEN protein stability. RSUME 
overexpression strongly reduced PTEN ubiquitination 
levels in COS7 cells, indicative of enhanced protein 
stability (Figure 5A). The inhibitory role of RSUME 
on PTEN ubiquitination was further confirmed by 
silencing RSUME in COS7 cells (Figure 5B). PTEN-
K254R and the double mutant K254/266R displayed 
increased ubiquitination compared to wild type, while 
the single K266R mutation had a minor effect on PTEN 
ubiquitination. RSUME overexpression inhibited PTEN 
ubiquitination in the wild type as well as single mutants 
(K254R and K266R), suggesting that a single mutation at 
the sumoylation acceptor site is not sufficient to prevent 
RSUME-induced PTEN ubiquitination inhibition. When 
both PTEN sumoylation acceptor sites were mutated, 
RSUME overexpression had no inhibitory effect on PTEN 
ubiquitination. These results indicate that RSUME inhibits 
PTEN ubiquitination and that both sumoylation acceptor 
sites (lysine 254 and lysine 266) are indispensable for 
sustaining this effect (Figure 5C).
RSUME knockdown in BON1 cells showed 
decreased PTEN half-life during cycloheximide (CHX) 
treatment while it had little effect in the scramble 
transfected control cells (Figure 5D). Similarly, the 
sumoylation deficient PTEN-K254/266R displayed 
decreased protein half-life compared to WT-PTEN 
indicating the critical role of sumoylation for PTEN 
protein stabilization. RSUME overexpression significantly 
increased WT-PTEN protein stability, but it had little 
effect on protein stability of the double mutant K254/266R 
(Figure 5E). 
RSUME increases PTEN nuclear accumulation
PTEN nuclear localization is pivotal for its anti-
tumorigenic activity and is regulated by sumoylation 
[28, 29]. PTEN displayed differential sublocalization 
between the normal pancreas and PanNETs (Figure 6A, 
Table 1), similar to previous observation [30]. In 
the normal pancreas, PTEN had strong nuclear and 
cytoplasmic staining in insulin-producing islet cells 
(Figure 6A, left), whereas in PanNET samples, PTEN 
showed either loss of expression (Figure 6A, right) or 
predominantly cytoplasmic staining (Figure 6A, middle). 
Wild type GFP-PTEN was equally distributed in both 
the nucleus and cytoplasm while the PTEN mutants 
(K254R, K266R, K254/266R) showed predominantly 
cytoplasmic localization (Figure 6B, left). RSUME 
overexpression (red) dramatically increased nuclear 
PTEN accumulation (Figure 6B, right). Similar results 
were obtained in HEK293 and PTEN-null prostate PC3 
cells (Supplementary Figure 10). RSUME overexpression 
had only moderate effects on the nuclear translocation 
of the single PTEN-K254R and PTEN-K266R mutants 
but clearly reduced nuclear translocation double PTEN-
K254/266R mutant, which remained predominantly in 
the cytoplasm (Figure 6B, Supplementary Figure 10). In 
sum, RSUME facilitates PTEN nuclear accumulation by 
modifying its sumoylation status.
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RSUME knockdown alters tumorigenic factors 
and favors metastasis formation in an orthotopic 
tumor model
Our data show that loss of RSUME upregulates 
NF-κB and downregulates PTEN, and both these effects 
may contribute to enhanced PanNET tumorigenesis. 
We made orthotopic xenografts by implanting human 
pancreatic BON1 PanNET (scramble and RSUME-KD) 
cells into the pancreas of nude mice, which was proven to 
be a successful PanNET model [31]. All animals developed 
tumors in the pancreas by 9 weeks and the tumors from 
the RSUME-KD group showed much higher weight 
compared to scramble controls (1102.5 ± 78.5 versus 786 
± 56.2 mg, Supplementary Figure 12). BON1RSUME-KD tumor 
samples exhibited significantly higher Ki67 proliferation 
index (12.70 ± 1.07% in BON1RSUME-KD tumors versus 
10.15 ± 1.01% in BON1Scramble, P < 0.01) (Supplementary 
Figure 12), which is in line with the proliferation results 
in vitro (Supplementary Figure 11). BON1RSUME-KD displayed 
reduced chromogranin A (CgA) immunoreactivity 
compared to the scramble control (Figure 7A) indicating 
Figure 4: RSUME enhances SUMO-induced PTEN sumoylation. (A) PTEN mRNA expression was measured in RSUME 
overexpressing (right) and RSUME silenced (left) BON1 cells. β-actin was used for normalization. Immunoblot for PTEN was analyzed 
in RSUME silenced (left) and RSUME overexpressing (right) BON1 cells. β-actin was used for normalization. High-migration PTEN 
(H-PTEN). (b) Immunoprecipitation was performed with a PTEN antibody in BON1 cells followed by western blot using antibodies 
against PTEN and SUMO2. (c) GST-PTEN was incubated using an in vitro sumoylation assay mixture containing SUMO2 with or without 
RSUME. After incubation, reactions were stopped by adding loading buffer and subsequently an immunoblot was performed with anti-
PTEN antibody. (D) COS7 cells were co-transfected with HA-PTEN, wild type V5-RSUME or the mutated V5-RSUME (Y61A,P62A), 
His6-SUMO2 and V5-Ubc9. 48 h post-transfection, cells were lysed, purified by Ni-NTA and immunoblotted with indicated antibodies. 
(E) COS7 cells were co-transfected with HA-PTEN expression or sumoylation-deficient PTEN mutants (K254R, K266R, K254/266R), 
His6-SUMO2 and V5-RSUME plasmids. 48 h post-transfection, cells were lysed, Ni-NTA purified and immunoblotted with the indicated 
antibodies. (F) COS7 cells were transfected with HA-PTEN with or without V5-RSUME. 48 h post-transfection, cells were lysed with 
RIPA buffer (10% for Input), precipitated with PTEN antibody and subsequently immunoblot was performed with antibodies indicated. For 
all experiments, one representative experiment from two independent experiments with similar results is shown.
Oncotarget57886www.impactjournals.com/oncotarget
loss of neuroendocrine differentiation. BON1RSUME-KD 
derived tumors showed weak cytoplasmic HIF-1α 
immunoreactivity compared to the strong nuclear staining 
seen in BON1Scramble (Supplementary Figure 15). In addition, 
BON1RSUME-KD derived tumors showed slightly lower VEGF 
immunoreactivity (not shown) and mRNA expression 
compared to BON1Scramble (Supplementary Figure 13B). 
In contrast, BON1RSUME-KD tumors showed lower micro-
vessel density (MVD) compared to scramble control 
(44.8 ± 3.6/field versus 67.4 ± 6.3/field) as determined by 
CD31 immunostaining (Figure 7B).
BON1RSUME-KD tumors showed stronger 
immunoreactivity for the activated NF-kB subunit 
pp65/RelA-Ser536 and the NF-kB target IL-8 
(Supplementary Figures 13C, 14, 16), confirming our in 
vitro data. In addition, IL-8 transcripts were elevated in the 
BON1RSUME-KD tumors (Supplementary Figure 13C). In 
contrast, PTEN expression was significantly reduced in 
BON1RSUME-KD xenografts with predominantly cytoplasmic 
staining (Supplementary Figures 13D, 14, 17). BON1Scramble 
tumors showed strong expression (mostly nuclear) of 
PTEN, despite its pancreatic neuroendocrine tumor origin 
(Supplementary Figures 13D, 14, 17). Accordingly, 
activated pAkt-Ser473 immunoreactivity and protein 
levels were increased in BON1RSUME-KD tumors compared 
to the scramble controls (Supplementary Figures 14, 18).
Figure 5: RSUME inhibits PTEN ubiquitination and increases protein stability. (A) COS7 cells were transfected with 
HA-PTEN, His6-ubiquitin and V5-RSUME or a backbone construct pCEFL. 48 h post-transfection, cells were incubated with 5 µM 
MG132 or vehicle for 6 h. His-ubiquitinated (His-Ub) proteins were isolated from denatured whole-cell extracts and pulled down by nickel 
beads. Purified proteins and input samples (whole-cell extracts) were analyzed by western blotting with anti-PTEN and anti-V5 (RSUME) 
antibodies. Signal in His-Ub pull-down lanes corresponds to ubiquitinated PTEN. b-actin was used as a loading control. (b) COS7 cells were 
transfected with HA-PTEN, His6-ubiquitin and 10 µM siRSUME. 48 h posttransfection, cells were incubated with MG132, purified and 
immunoblotted with anti-PTEN and anti-RSUME. β-actin was used as a loading control. (c) COS7 cells were transfected with HA-PTEN 
or different mutants (K254R, K266R, K254/266R), V5-RSUME and His6-Ubiquitin. 48 h post-transfection, cells were incubated with 
MG132, purified and immunoblotted with anti-PTEN and anti-RSUME. One representative experiment from two independent experiments 
with similar results is shown. (D) BON1RSUME-KD and BON1Scramble cells were treated with cycloheximide (CHX) for the time indicated. Cell 
lysates were collected and subjected to immunoblot using antibodies against PTEN and RSUME. β-actin was used as the loading control. 
(E) COS7 cells were co-transfected with wild type or sumoylation-deficient PTEN mutant (K254/266R) with or without V5-RSUME. 48 h 
post-transfection, cells were treated with cycloheximide for the indicated time points and immunoblotted with the indicated antibodies. 
β-actin was used as the loading control.
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Five of eight (62.5%) mice injected with 
BON1RSUME-KD cells developed liver metastasis, evidenced 
grossly and histologically by H&E staining (Figure 
7C, 7D). In contrast, only one out of eight (12.5%) 
mice injected with BON1Scramble cells developed liver 
metastasis. Markers for epithelial-mesenchymal transition 
(EMT), such as TGFβ, Snail, N-cadherin increased, while 
E-cadherin decreased in BON1RSUME-KD tumors, indicating 
that loss of RSUME promotes EMT (Figure 7E). 
Altogether, our data show that loss of RSUME in PanNET 
cells results in PTEN loss and supports PanNET tumor and 
metastasis formation.
DIscUssION
In the present study, we demonstrate for the first 
time that the expression of RSUME is altered in PanNETs 
and present in vitro and in vivo data which strongly 
suggest that the reduction of RSUME contributes to the 
tumorigenesis and metastasis in PanNETs. RSUME is 
highly expressed in various endocrine/exocrine glands, 
including the pancreas [17]. We could show that RSUME 
is mainly localized in insulin-producing beta-cells and is 
also present in other endocrine and exocrine pancreatic 
cell types whereas it is not expressed in the ductal cells, 
Figure 6: RSUME influences PTEN localization in normal and tumoral pancreatic cells. (A) Immunofluorescence studies 
showed that in the normal pancreas, PTEN (red) is predominantly localized in the nuclei of insulin-producing cells (green) (A, left) 
whereas in PanNETs PTEN is present in the cytoplasm of tumor cells (A, middle) or completely absent (A, right). PTEN showed both 
nuclear and cytoplasmic expression in BON1 cells transfected with GFP-PTEN (green) whereas the PTEN sumoylation deficient double 
mutant (K254/266R) (green) is localized only in the cytoplasm (b, left). Over-expression of RSUME (red) in GFP- or K254/266R-PTEN 
expressing BON1 cells strongly increased nuclear PTEN (green) expression in cells with GFP-PTEN whereas PTEN remained in the 
cytoplasm of cells expressing the K254/266R mutant (B, right). Cell nuclei were visualized using DAPI (blue). Scale bar: 10 μm.
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indicating a distinct physiological role of RSUME in 
endocrine and exocrine functions of the pancreas. Whereas 
RSUME expression was preserved in all insulinomas 
studied, RSUME was mostly absent in other types of 
hormone-producing and in hormone-negative PanNETs. 
As most of the insulinomas are considered to represent 
well-differentiated, benign tumors we speculate that the 
loss of RSUME is associated with the development of 
more aggressive, less well-differentiated PanNETs. After 
this first description on the role of RSUME in PanNETs, 
clinical correlation studies are needed to establish the 
association that RSUME might have whit different types 
of tumors.
Tumor expansion is accompanied by transient 
hypoxia, which triggers tumor neovascularization. 
Hypoxia induces RSUME, which was found to be 
upregulated in the hypoxic inner zones of gliomas and 
pituitary adenomas [17, 32]. In breast cancer, RSUME 
(RWDD3) has been associated with 15 other genes as part 
of the risk prediction signature [33]. In a GWAS performed 
in 2204 breast cancer patients RWDD3 was associated 
with paclitaxel-induced neuropathy [34], which however 
could not be confirmed in a cohort of paclitaxel-treated 
patients with ovarian cancer [35]. Alterations of RSUME 
have also been associated with chronic inflammation-
induced neuropathic pain [36].
Hypoxia up-regulated RSUME in the PanNET-
derived BON1 cell line, but in PanNETs RSUME 
was down-regulated suggesting the presence of other 
more important regulatory mechanisms. Inflammatory 
processes play an important role in the development of 
pancreatic adenocarcinomas [2] and may be responsible 
for the RSUME down-regulation in PanNETs. 
Indeed, TNF-a which was reported to be produced 
intratumorally in PanNETs [36], strongly suppressed 
RSUME (Supplementary Figure 19). These finding 
are in accordance with a recent study in which chronic 
inflammation reduced the transcription of RWDD3/
RSUME and anti-inflammatory acting drugs could revert 
this effect [36].
Figure 7: Role of RSUME in an orthotopic neuroendocrine pancreatic tumor model. Orthotopic tumors from BON1 cells 
without (scramble) or with RSUME knockdown (RSUME-KD) were generated by injecting the cells into the pancreas of athymic nude 
mice. In comparison to scramble tumors, RSUME-KD tumors showed reduced chromogranin A staining (brown) indicative of a loss of 
neuroendocrine differentiation (A). RSUME-KD tumors are significantly less vascularised (CD31 staining) than scramble tumors (b) 
but show strongly enhanced spread of metastases into the liver as shown morphologically (c) and immunohistochemically by detecting 
CgA-positive neuroendocrine tumor tissue in the nude mouse liver (D). Tumors with RSUME-KD show reduced PTEN expression and 
signs of epithelial-mesenchymal-transition (EMT) such as enhanced TGF-β, N-Cadherin and Snail protein levels as well as reduced 
E-Cadherin protein expression (E) indicating that loss of RSUME promotes EMT in PanNETs. Microvessel density in the right panel in 
B was determined by counting of the number of vessels in one field under 100× magnification. Results were obtained from 6 independent 
pictures for each condition and are expressed as mean ± SEM. *P < 0.05 vs. scramble tumors. Scale bar 100 µm.
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Loss of RSUME abolished the stimulatory effect 
of hypoxia on HIF-1α, but not on VEGF-A, suggesting 
the presence of an alternative compensatory mechanism. 
We have previously shown that RSUME inhibits NF-κB 
by stabilizing its inhibitor I-κBα [17]. NF-κB stimulates 
VEGF-A transcription directly by binding its promoter 
or indirectly through IL-8 expression, which acts in an 
autocrine fashion [21, 24]. Our data show that loss of 
RSUME induces IL-8 synthesis, which then triggers 
VEGF-A, an effect that is abolished using an IL-8 receptor 
CXCR2 inhibitor. Poorly differentiated PanNETs are 
less vascularized than well-differentiated tumors [15]. 
Furthermore, high expression of IL-8 and CXCR2 was 
observed in the human PanNET patient samples [21]. 
Thus, the NF-κB/IL-8 pathway may compensate 
the decline of HIF-1 action on VEGF-A-mediated 
angiogenesis in PanNET cells that have lost RSUME. 
This may explain why neovascularization is maintained 
in advanced PanNETs despite RSUME down-regulation. 
Another important target, which is inhibited by NF-κB 
is PTEN [27]. PTEN is reduced in PanNETs and its 
expression is inversely correlated with survival [13, 14]. 
PTEN loss is rarely caused by genetic mutations in 
PanNETs and the mechanism remains unclear [11, 30]. In 
the present study, we describe for the first time that the 
tumor suppressor PTEN is a target of RSUME. Loss of 
RSUME in a PanNET model in nude mice is accompanied 
by a decrease in PTEN, which may be in part due to the 
upregulation of NF-κB that suppresses PTEN transcription 
[27]. In addition, recent studies demonstrated that PTEN 
is sumoylated [28, 38] and herein, we show that RSUME 
enhances PTEN sumoylation and its activity. This action 
on PTEN reinforces the role of RSUME on several 
specific targets related to cancer and inflammation, such as 
HIF-1a, I-κB, GR and pVHL [17, 18, 23, 32, 39]. Whether 
the observed loss of RSUME in the majority of human 
PanNETs studied is responsible for the cytoplasmatic 
localization or complete loss of PTEN in our series of 
human PanNETs needs to be confirmed in future studies.
Loss of RSUME is accompanied by decreased PTEN 
sumoylation and increased Akt phosphorylation, which may 
contribute to the PI3K pathway over-activation observed 
in high grade PanNETs [11, 14]. The decreased PTEN 
sumoylation impairs its cellular distribution. Cytosolic 
PTEN suppress the PI3K survival pathway, while nuclear 
PTEN controls DNA damage repair, genotoxic stress, 
chromosome stabilization and growth [29, 40, 41]. Our 
data show that RSUME sumoylates PTEN and increases 
its nuclear accumulation. Indeed, sumoylated PTEN is 
located in the nucleus, where it induces DNA repair upon 
genotoxic stress [29, 40]. Therefore, the observed RSUME 
down-regulation leads to loss of nuclear PTEN, which 
would result in impaired chromosome stabilization [40, 41].
Increased chromosomal instability renders the 
tumor cell susceptible to additional mutations that increase 
its tumorigenic and metastatic potential [2, 13, 14, 42]. 
Herein, we demonstrate that loss of RSUME results in high 
metastatic potential in orthotopic pancreatic transplants. We 
have chosen the orthotopic transplantation in the pancreas 
compared to subcutaneous transplantation, because it mimics 
the human PanNET condition and the metastasis formation 
of the tumors in the neighboring structures of the pancreas, 
in particular in the liver, can be monitored [30, 43]. Tumors 
of BON1 cells with RSUME knockdown formed multiple 
liver metastases that may be a consequence of increased 
NF-κB expression and/or loss of PTEN [12, 30, 44]. The 
BON1RSUME-KD-derived tumors were also much larger, 
had higher proliferation rates and signs of high-grade less 
well-differentiated tumors as shown by morphological 
H&E staining and decreased CgA expression. In addition, 
microvessel density was low in these tumors similar to what 
is observed in the human PanNETs [15].
Our data demonstrate that RSUME affects multiple 
targets in PanNET cells and as long as RSUME expression 
is preserved, these tumors show relatively low proliferation 
rates, expand slowly and have a limited metastatic 
potential despite elevated angiogenesis and enhanced 
microvessel density. The decline of RSUME in PanNETs 
goes along with reduced HIF-1α/VEGF-A, elevated 
NF-κB/IL-8, declined PTEN and enhanced PI3K/Akt/
mTOR activation. These multiple changes may explain 
why mono-targeting pharmacological treatment concepts 
often failed in tumor therapy and therefore combined 
application of drugs directed against different targets gave 
better results [5–8]. Altogether, our findings demonstrate 
considerable evidence that loss of RSUME is involved 
in the increase of tumor aggressiveness and metastases 
formation in PanNETs. After our first description on the 
involment of RSUME in PanNET, further studies with 
higher numbers of PanNETs are needed in which the 
correlations between RSUME expression and histological 
characteristics of the tumors as well as clinical parameters 
and outcome of affected patients are investigated.
MAtErIALs AND MEtHODs
Human tissue samples
Paraffin-embedded tissue slides of 9 normal 
pancreas tissue samples, 24 human pancreatic 
neuroendocrine tumors and intraoperatively removed 
adjacent normal human pancreatic tissue were obtained 
from the Department of Pathology of the Technical 
University Munich, Germany. The histopathological 
diagnosis and grading, as well as staging followed the 
recommendations of the WHO (Table 1). Sampling of 
tissues and usage of clinical data for scientific purposes 
was approved by the institutional ethics committee.
cell lines and reagents
Human pancreatic endocrine tumor BON1 cells 
used in the study were authenticated by Eurofins 
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(Ebersberg, Germany). HEK293 cells and COS7 cells 
were obtained from American Type Culture Collection 
(ATCC; Manassas, VA, USA) and were cultured - like 
BON1 cells - at 5% CO2 and 37°C in DMEM (pH 7.3) 
supplemented with 10% FCS, 2mM glutamine, 0.5 mg/l 
partricin and 105 U/liter penicillin-streptomycin. In 
addition to BON1 cells, human pancreatic endocrine 
carcinoma QGP-1 cells were used for several control 
experiments as some authors suggest that QGP1 cells were 
a better model for PanNETs. However, in a recent study 
only limited differences between the two cell types were 
found [45]. QGP1 cells were obtained from the Health 
Science Research Resources Bank (Osaka, Japan) and 
maintained in RPMI1640 medium supplemented with 10% 
FCS, 2mM glutamine, 0.5 mg/l partricin and 105 U/liter 
penicillin-streptomycin. Cell culture materials and 
reagents were obtained from Life Technologies, Falcon 
(Heidelberg, Germany), Nunc (Wiesbaden, Germany), 
Seromed (Berlin, Germany), Flow Cytometry Standards 
Corp. (Meckenheim, Germany) and Sigma. Cobalt 
chloride (CoCl2) was purchased from Sigma. For hypoxia, 
cells were incubated in 2% serum at 37°C, 5% CO2, and 
1% O2 balanced with N2 using a hypoxic chamber ProOx 
Model 110 (BioSpherix).
RNA isolation and RT-PCR
Total RNA was extracted from cells and tumor 
tissues with Trizol reagent (Life Technology) according 
to the manufacture’s instruction. 500 ng total RNA 
was reverse transcribed using Oligo-dT under standard 
conditions provided by the manufacture (Life technology). 
Quantitative real-time PCR was performed on a 
LightCycler (Roche) using LightCycler FastStart DNA 
Master SYBR Green Plus (Roche) in a final volume of 
10 μl. Primer sequences and conditions for RT-PCR are 
listed in Supplementary Table 1. Expression levels of 
the housekeeping genes human β-actin were used for 
normalization.
Transfection and generation of target-specific 
silent cells
All constructs used in this study are listed in 
Supplementary Table 2. Sumoylation deficient PTEN 
mutations (K254R, K266R, K254/266R) were generated 
by site-directed mutagenesis assay as described previously. 
Transfection assay was performed with lipofectamin 2000 
following the manufacturer’s instructions. The reporter 
constructs (HRE-Luc, RSUME-Luc, RSUME-∆HRE-Luc, 
IL-8-Luc, IL-8-∆-NFκB-Luc) were described previously. 
500 ng of reporter constructs with 300 ng β-galactosidase 
were co-transfected into BON1 cells and luciferase 
activity was measured with the Dual Luciferase Reporter 
Assay System (Promega). The relative luciferase activity 
was calculated by the ratio of luciferase/ β-gal activity. 
For stable RSUME knockdown generation, the plasmids 
encoding shRSUME or scramble RNA (SABiosciences, 
USA) were transfected with lipofectamin 2000 into the 
BON1 cells according to the standard protocol. The stable 
clones were selected with Geneticin (Life Technologies) 
at a concentration of 1 mg/ml. After the selection, stable 
clones with RSUME knockdown (BON1RSUME-KD) and 
scramble (BON1Scramble) were cultured in medium with 
500 µg/ml Geneticin and used at passage 4 and 5. RSUME 
expression level was validated by RT-PCR and western 
blot. All the data shown were from one individual clone 
designated No.15; similar results were obtained in other 
individual clones as well as in transient expression assays.
Western blot and antibodies
Western blot analysis was carried out on whole cell 
extracts (50 µg) upon various treatments, after fractionation 
by PAGE gel electrophoresis and transferred to PVDF 
membranes for immunoblotting with antibodies listed 
in Supplementary Table 3. HRP-conjugated secondary 
antibodies against rabbit and mouse were all obtained 
from Cell Signalling Tech. The ECL system (Clarity ECL 
substrate, Biorad) and hyperfilm (GE Healthcare, Munich, 
Germany) were used for membrane visualization.
ELIsA
Measurement of VEGF-A and IL-8 secretion in cell 
culture supernatant was performed with ELISA kits (R&D 
Systems, Wiesbaden, Germany) for human VEGF-A and 
human IL-8 according to the manufacturer’s instruction. 
All the experiments were carried out in quadruplicates.
Immunoprecipitation
Cells for immunoprecipitation assay were lysed in 
Immunoprecipitation lysis buffer (25 mM Tris PH 8.0, 
150 mM NaCl, 1% NP-40, 1 mM EDTA, 20 mM NEM) 
containing protease inhibitor cocktail (1:100, Sigma). The 
whole cell lysates obtained from centrifugation were first 
precleared by Dynabeads Protein G magnetic (Invitrogen) 
for 1 hour and then incubated with specific antibodies 
(PTEN, # 9558, Cell Signaling, 1:100) overnight at 4°C 
with rotation. The protein G magnetic beads were added 
the following day to the lysates and further incubate for 
2 hours at 4°C with rotation. The immunocomplexes were 
then washed with Immunoprecipitation lysis buffer three 
times and then boiled with sample loading buffer and 
subjected to SDS-PAGE followed by western blot analysis.
In vitro sumoylation assay
The His-tagged recombinant protein pQE30, 
pQE30-RSUME were transformed into E. Coli M15 
(pREP4) cells with the Qiaexpress kit according to the 
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manufacturer’s instructions. GST-PTEN expressed in 
E.Coli DH5α and purified with glutathione-sepharose 4B 
beads (GE Healthcare) as specified by the manufacture. 
The protein concentration was measured by Bradford 
(Biorad) and then recombinant proteins were validated by 
western blot for the correct expression.
In vitro sumoylation conjunction assay was 
performed using SUMO kit from Enzo bioscience. 
Specifically, 250 ng GST-PTEN and mutants, 1 μl of 
SUMO2, 1 μl Aos1&Uba2, 1 μl Ubc9, and 2 μl 10× 
reaction buffer with or without 1 μl ATP; H2O was added 
to make the final volume of 20 μl. The reaction mixture 
was incubated at 37°C for 2 hours and stopped by adding 
sample loading buffer. The reaction mixture was separated 
by SDS-PAGE and subsequently immunoblotted with anti-
PTEN antibody to detect SUMO modified PTEN.
Sumoylation conjugation assay in cells
COS7 cells were transfected with either control 
plasmid or V5-RSUME plasmid together with His-
SUMO1/2 and V5-Ubc9. 48 hours post-transfection, cells 
were harvested in PBS with protease inhibitor and divided by 
two parts. 10% of the cells were preserved as input in SDS-
PAGE loading buffer and subjected to WB. The remaining 
cells were first centrifuged then lysed in Ni-NTA lysis buffer 
and subsequently subjected to protein purification by Nickel 
magnetic Sepharose beads overnight at 4°C. The beads 
were collected, washed 3 times with washing buffer and 
the antigen-antibody complexes were recovered by boiling 
in SDS-PAGE sample buffer. The input and samples were 
subjected to Western blot with anti-PTEN antibody.
Ubiquitination assay in cells
COS7 cells were transfected with various plasmids as 
indicated in individual experiment. 48 h after transfection, 
cells were treated with 10 μM MG132 for 6 h, and the 
whole cell lysates were prepared with immunoprecipitation 
lysis buffer containing protease inhibitor cocktail and were 
subjected to Immunoprecipitation with anti-HA antibody. 
The immunoprecipitated HA-PTEN were released from 
the beads by boiling in SDS-PAGE sample buffer. The 
analysis of PTEN ubiquitination was carried out by 
immuno-blotting with anti-PTEN antibody.
Protein half-life assay
COS7 cells were transfected with 1 μg/well of 
HA-PTEN (wild type and mutants) plasmids and 1 μg 
RSUME plasmid or control plasmid. 48 h after transfection, 
100 μg/ml cycloheximide (CHX) was added to each well 
for various time points as indicated. Whole cell lysates 
were obtained and protein concentration was determined 
by Bradford assay followed by immunoblot with anti-HA 
antibody. β-actin was used as a loading control.
tumor implantation
Female nude mice (4–6 weeks) were used for 
tumor transplantation. Animal care followed institutional 
guidelines and experiments were approved by local 
animal research authorities. Mice were anaesthetized by 
intraperitoneal administration of Ketavel and Rompun as 
following the standard protocol. For tumor induction, the 
pancreas was exposed and 50 μl matrigel and BON1 cell 
mixture (1:1, 5 × 105) were injected into the head of the 
pancreas. After 9 weeks, mice were sacrificed; primary 
tumors and liver were collected.
Immunohistochemistry and immunofluorescence
For immunocytofluorescence experiments, cells 
or cryostat cut (5 μm) tumor tissues were fixed in 4% 
paraformaldehyde for 5 minutes, and then blocked in 
5% goat serum with 0.1% (v/v) triton X100 for 1 hour 
at room temperature. Slides were incubated with the 
indicated antibodies overnight at 4°C and then washed 
and incubated with Alexa Fluor® 594 goat anti-rabbit 
antibody (1:500, Invitrogen) or FITC-488 goat anti-mouse 
(Invitrogen) antibody at room temperature for 2 hours. 
After washing with PBS, ProLong® Gold antifade reagent 
with DAPI (Invitrogen) was used for mounting and 
visualization of cell nuclei. Images were obtained using a 
confocal microscope (Fluo View TM FV1000, Olympus). 
Images were obtained using 40× objectives. The 
antibodies used for staining are listed in Supplementary 
Table 4. For human pancreatic neuroendocrine tumors as 
well as normal pancreas slides, paraffin embedded samples 
were first subjected to deparaffinization and citric acid 
based antigen retrieval was performed following standard 
protocols. Sections were either stained with hematoxylin 
and eosin (H&E) or subjected to immunohistochemistry 
or immunofluorescence. Antibodies used in this study are 
listed in Supplementary Table 4. Immunohistochemistry 
images were obtained with light microscope (Zeiss, 
Germany) with 20× objectives. Immunofluorescence 
images were obtained using confocal microscope (Fluo 
ViewTM FV1000, Olympus). Images were obtained using 
60× objectives. 
Determination of microvessel density and Ki67 
index in mouse xenografts
For quantification of microvessel density (MVD), 
the average number of CD31 positive vessels in a 0.6 mm2 
(10×) measurement area was determined from 4 regions 
of maximal vascular density from control and RSUME 
knockdown tumors (n = 6). Ki67 index was obtained 
by counting the ratio of Ki67 positive cells versus total 
nuclei (DAPI). 4 randomly selected images were chosen 
from control and RSUME knockdown tumors (n = 6) for 
calculation (Imagine J, NIH).
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Statistical analysis
Each of the experiments was repeated at least three 
times. The individual experiments were performed in 
quadruplicate wells. All data are presented as mean ± SEM 
unless otherwise specified. For all two-way comparisons, 
unpaired t-tests were used. Statistical analysis was 
performed using the unpaired Student’s t-test and were 
considered statistically significant if P < 0.05.
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